Savara Inc (NASDAQ:SVRA) Receives $11.17 Average Price Target from Analysts

Savara Inc (NASDAQ:SVRA - Get Free Report) has been assigned an average rating of "Buy" from the six ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.17.

Several equities research analysts have recently weighed in on SVRA shares. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Savara in a research report on Tuesday, October 8th. JMP Securities reissued a "market outperform" rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st.

Savara Stock Performance

NASDAQ:SVRA traded down $0.10 during mid-day trading on Tuesday, reaching $3.97. The stock had a trading volume of 307,967 shares, compared to its average volume of 1,198,878. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The firm has a market capitalization of $653.46 million, a price-to-earnings ratio of -9.69 and a beta of 1.02. Savara has a twelve month low of $3.28 and a twelve month high of $5.70. The business has a 50 day simple moving average of $3.97 and a 200 day simple moving average of $4.22.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Savara by 92.3% during the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company's stock valued at $366,000 after purchasing an additional 35,269 shares during the period. Swiss National Bank acquired a new position in Savara during the first quarter valued at approximately $732,000. Susquehanna Fundamental Investments LLC acquired a new position in Savara during the first quarter valued at approximately $394,000. ProShare Advisors LLC grew its holdings in Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company's stock valued at $128,000 after purchasing an additional 2,114 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company's stock valued at $30,197,000 after purchasing an additional 148,673 shares during the period. Institutional investors and hedge funds own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.